Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review
- 1k Downloads
Olanzapine is an atypical antipsychotic drug that inhibits serotonergic, dopaminergic, alpha-1 adrenergic, histaminic, and muscarinic receptors. Several phase I and II trials have been published documenting the use of olanzapine in controlling chemotherapy-induced nausea and vomiting (CINV). This review aims to summarize all phase I and II trials that reported on olanzapine for the prophylaxis of CINV.
A literature search was conducted in Ovid MEDLINE from 1946 to July week 1 2015, Embase Classic and Embase from 1947 to 2015 week 28, and the Cochrane Central Register of Controlled Trials up until June 2015. Phase I and II trials reporting on olanzapine for the prophylaxis for CINV were included if they reported on at least one of four primary endpoints: complete response (CR), complete control (CC), no nausea, and no emesis. Other endpoints of interest included the safety of olanzapine as measured by the M.D. Anderson Symptom Inventory.
Across the seven included studies, there were a total of 201 patients. The CR across four studies was 97.2, 83.1, and 82.8 % for the acute, delayed, and overall phases, respectively. The CC for acute, delayed, and overall phases was 92.5, 87.5, and 82.5 %, respectively. The overall no nausea rate was 92.7, 71.8, and 70.6 % for the acute, delayed, and overall phases, respectively. The overall no emesis rates for the acute, delayed, and overall phases were 100, 94.5, and 90.4 %, respectively. Fatigue, drowsiness, and disturbed sleep were common side effects.
Olanzapine is efficacious and safe when used as a prophylaxis for CINV.
KeywordsOlanzapine Chemotherapy-induced nausea and vomiting Prophylaxis Efficacy Safety
We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.
Compliance with ethical standards
Conflict of interest
- 5.Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S et al. (2015) Efficacy and safety of olanzapine combined with aprepitant, palonosetron and dexamethasone for preventing nausea and vomiting by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1303 phase II trial. Supp Care Canc. doi: 10.1007/s00520-015-2829-z
- 6.Park S, Choi C, Kwon M, Tae J, Kim H (2015) A phase II trial of palonosetron and olanzapine without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Supp Care Canc 23(Suppl 1):S147Google Scholar